Skip to main content
. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853

Figure 1.

Figure 1.

Elotuzumab promotes NK cell degranulation that correlates with SLAMF7 expression on myeloma target cell lines. A) NK cell degranulation (CD107a+) from a representative healthy donor after 2 hours incubation with MM.1R targets alone (left; PBMC to target ratio 1:1) or with 1µg/ml Elo. Percentage degranulating CD56dim NK cells is indicated in the box gates. B) SLAMF7 expression on myeloma target cell lines using biotinylated Elo and streptavidin-APC. Unstained cells = gray shaded, parental RPMI8226 = dotted (MFI 422), SLAMF7-transduced RPMI8226 = dashed (MFI 2254), and MM.1R = solid (MFI 10,973). C) Degranulation responses by NK cells in PBMCs from healthy donors (n = 7) alone (circles) or exposed to RPMI-8226 (inverted triangles), RPMI-8226+SLAMF7 (squares) or MM.1R target cells (diamonds) in the presence (+; filled) or absence (-; empty) of 1µg/ml Elo. Horizontal lines = medians; each datapoint = a healthy donor. Overhead bars mark statistical comparisons between indicated groups using one-sided or 2-sided Wilcoxon matched-pairs signed rank test, **- P < 0.01, *-P < 0.05.